Clinical Trials on Metastatic Castration-resistant Prostate Cancer (mCRPC)

Total 1163 results

Pfizer

Completed

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Metastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Finland
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
FutureChem

Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (LUCIDA_2)

Metastatic Castration-resistant Prostate Cancer, mCRPC

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Constellation Pharmaceuticals

Active, not recruiting

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Avionco LLC

Completed

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Russian Federation
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
Translational Research Center for Medical Innovation...

Completed

A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC (DELC)

Castration Resistant Prostate Cancer (CRPC)
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Myovant Sciences GmbH

Recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
Tiltan Pharma Ltd.

Unknown

Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) (TLH-202)

Metastatic Castration Resistant Prostate Cancer (CRPC)

Israel
Universität des Saarlandes

Recruiting

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Prostate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic Cancer

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Healthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100

Germany
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
British Columbia Cancer Agency

Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Canada
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Advanced Accelerator Applications

No longer available

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Inmune Bio, Inc.

Recruiting

Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe)

Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic Neoplasms

United States
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clarus Therapeutics

Recruiting

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
SL VAXiGEN

Recruiting

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Korea, Republic of
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Metastatic Castration-resistant Prostate Cancer, mCRPC
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States, Puerto Rico, Israel, Australia, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain
University of Oklahoma
Dendreon

Recruiting

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (OUSCCEXCITE)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Dendreon

Not yet recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T (ProvONE)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Peter MacCallum Cancer Centre, Australia

Suspended

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Italy
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Metastatic Prostate Cancer | Castration Resistant Prostatic Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Metastatic Castration-resistant Prostate Cancer

China
Hinova Pharmaceuticals Inc.

Completed

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Metastatic Castration Resistant Prostate Cancer

China
Radboud University Medical Center
Astellas Pharma Europe B.V.

Completed

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Sun Yat-sen University

Recruiting

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Metastatic Castration-resistant Prostate Cancer

China
Syneos Health
Antares Pharma Inc.

Withdrawn

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Metastatic Castration-resistant Prostate Cancer
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States

Clinical Trials on Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations